Brief: Silence Therapeutics Announces FDA Fast Track Designation For Sln124, A Novel Investigational Sirna Therapy For The Treatment Of Polycythemia Vera
08/09/2022 13:36
Sept 8 (Reuters) - Silence Therapeutics PLC SLNCF.PK :
* SILENCE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION
FOR
SLN124, A NOVEL INVESTIGATIONAL SIRNA THERAPY FOR THE TREATMENT
OF POLYCYTHEMIA VERA
* SILENCE THERAPEUTICS PLC - PLANS TO START A PHASE 1/2
STUDY IN
PV PATIENTS THIS YEAR
Source text for Eikon: ID:nBw4gCn4ya
Further company coverage: SLNCF.PK
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing